NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 5.64% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 5.31% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 4.88% |
| ARGX | argenx NV ADR | Healthcare | Biotechnology | 4.80% |
| BPMC | Blueprint Medicines Corp | Healthcare | Biotechnology | 4.69% |
| INCY | Incyte Corporation | Healthcare | Biotechnology | 4.33% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 4.21% |
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 4.16% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | Drug Manufacturers - General | 3.65% |
| EXEL | Exelixis Inc | Healthcare | Biotechnology | 3.63% |
| IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
| 4568 | Daiichi Sankyo Co. Ltd. | Healthcare | Drug Manufacturers - General | 2.97% |
| GH | Guardant Health Inc | Healthcare | Diagnostics & Research | 2.63% |
| MREO | Mereo BioPharma Group PLC ADR | Healthcare | Biotechnology | 2.47% |
| GMAB | Genmab AS | Healthcare | Biotechnology | 2.41% |
| SWTX | SpringWorks Therapeutics Inc | Healthcare | Biotechnology | 2.39% |
| CRSP | Crispr Therapeutics AG | Healthcare | Biotechnology | 2.34% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 2.32% |
| BGNE | BeiGene Ltd | Healthcare | Biotechnology | 2.25% |
| AGIO | Agios Pharm | Healthcare | Biotechnology | 2.25% |